Cargando…

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combination the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiaie, Seyed Hossein, Salehi-Shadkami, Hossein, Sanaei, Mohammad Javad, Azizi, Marzieh, Shokrollahi Barough, Mahdieh, Nasr, Mohammad Sadegh, Sheibani, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512572/
https://www.ncbi.nlm.nih.gov/pubmed/37735656
http://dx.doi.org/10.1186/s12951-023-02083-y
_version_ 1785108390381355008
author Kiaie, Seyed Hossein
Salehi-Shadkami, Hossein
Sanaei, Mohammad Javad
Azizi, Marzieh
Shokrollahi Barough, Mahdieh
Nasr, Mohammad Sadegh
Sheibani, Mohammad
author_facet Kiaie, Seyed Hossein
Salehi-Shadkami, Hossein
Sanaei, Mohammad Javad
Azizi, Marzieh
Shokrollahi Barough, Mahdieh
Nasr, Mohammad Sadegh
Sheibani, Mohammad
author_sort Kiaie, Seyed Hossein
collection PubMed
description Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combination therapies through novel immune checkpoint inhibitors (ICIs) has been limited due to immune-related adverse events (irAEs), low response rate, and lack of optimal strategy for combinatorial cancer immunotherapy (IMT). Nanoparticles (NPs) have emerged as powerful tools to promote multidisciplinary cooperation. The feasibility and efficacy of targeted delivery of ICIs using NPs overcome the primary barrier, improve therapeutic efficacy, and provide a rationale for more clinical investigations. Likewise, NPs can conjugate or encapsulate ICIs, including antibodies, RNAs, and small molecule inhibitors. Therefore, combining the drug delivery system (DDS) with ICP therapy could provide a profitable immunotherapeutic strategy for cancer treatment. This article reviews the significant NPs with controlled DDS using current data from clinical and pre-clinical trials on mono- and combination IMT to overcome ICP therapeutic limitations. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10512572
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105125722023-09-22 Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy Kiaie, Seyed Hossein Salehi-Shadkami, Hossein Sanaei, Mohammad Javad Azizi, Marzieh Shokrollahi Barough, Mahdieh Nasr, Mohammad Sadegh Sheibani, Mohammad J Nanobiotechnology Review Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combination therapies through novel immune checkpoint inhibitors (ICIs) has been limited due to immune-related adverse events (irAEs), low response rate, and lack of optimal strategy for combinatorial cancer immunotherapy (IMT). Nanoparticles (NPs) have emerged as powerful tools to promote multidisciplinary cooperation. The feasibility and efficacy of targeted delivery of ICIs using NPs overcome the primary barrier, improve therapeutic efficacy, and provide a rationale for more clinical investigations. Likewise, NPs can conjugate or encapsulate ICIs, including antibodies, RNAs, and small molecule inhibitors. Therefore, combining the drug delivery system (DDS) with ICP therapy could provide a profitable immunotherapeutic strategy for cancer treatment. This article reviews the significant NPs with controlled DDS using current data from clinical and pre-clinical trials on mono- and combination IMT to overcome ICP therapeutic limitations. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2023-09-21 /pmc/articles/PMC10512572/ /pubmed/37735656 http://dx.doi.org/10.1186/s12951-023-02083-y Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Kiaie, Seyed Hossein
Salehi-Shadkami, Hossein
Sanaei, Mohammad Javad
Azizi, Marzieh
Shokrollahi Barough, Mahdieh
Nasr, Mohammad Sadegh
Sheibani, Mohammad
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
title Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
title_full Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
title_fullStr Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
title_full_unstemmed Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
title_short Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
title_sort nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512572/
https://www.ncbi.nlm.nih.gov/pubmed/37735656
http://dx.doi.org/10.1186/s12951-023-02083-y
work_keys_str_mv AT kiaieseyedhossein nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy
AT salehishadkamihossein nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy
AT sanaeimohammadjavad nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy
AT azizimarzieh nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy
AT shokrollahibaroughmahdieh nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy
AT nasrmohammadsadegh nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy
AT sheibanimohammad nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy